J&J, AbbVie and others to showcase trispecific antibody data at ASH 2026
The three-pronged cancer therapies could mark another advance in treating multiple myeloma.
Read at Biopharmadive โFull coverage ยท 3 outlets
- Biopharmadive ยท lead
- BioPharma DiveAt ASH, drugmakers to showcase early data for three-pronged cancer therapies
- Morningstar2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple ...